Loading...
Docoh

Exelixis (EXEL)

News

From Benzinga Pro
Recap: Exelixis Q2 Earnings
9 Aug 22
Earnings
Exelixis (NASDAQ:EXEL) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement.
Exelixis Q2 EPS $0.28 Beats $0.19 Estimate, Sales $419.43M Beat $390.91M Estimate
9 Aug 22
Earnings, News
Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.19 by 47.37 percent. This is a 24.32 percent decrease over earnings of $0.37 per share from the same
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
9 Aug 22
Biotech, Earnings, Government, News, Penny Stocks, Health Care, Financing, Offerings, Contracts, Small Cap, FDA, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Scheduled For August 9, 2022
9 Aug 22
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter.
Piper Sandler Maintains Overweight on Exelixis, Raises Price Target to $32
26 Jul 22
News, Price Target, Analyst Ratings
Piper Sandler analyst Do Kim maintains Exelixis (NASDAQ:EXEL) with a Overweight and raises the price target from $30 to $32.
Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $23
15 Jul 22
News, Price Target, Analyst Ratings
Morgan Stanley analyst Jeffrey Hung maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $22 to $23.
Exelixis Says Cabozantinib In Combination With Nivolumab And Ipilimumab Improved Progression-Free Survival In Phase 3 COSMIC-313 Pivotal Trial In Patients With Previously Untreated Advanced Kidney Cancer
11 Jul 22
News, FDA
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney
The Daily Biotech Pulse: Merck's Seagen Buyout Advances, Adverum Restructures, Pharmacists Get OK To Prescribe Pfizer COVID-19 Pill
7 Jul 22
Biotech, M&A, News, Penny Stocks, Health Care, Rumors, Contracts, Small Cap, FDA, Insider Trades, Stock Split, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Exelixis to Pay Ryvu an Upfront Fee of $3M in Exchange for Certain Rights to Ryvu's Sting Agonist Small Molecules
7 Jul 22
News
Exelixis, Inc. (Nasdaq: EXEL) and Ryvu Therapeutics S.A. ("Ryvu") (Warsaw Stock Exchange: RVU) today announced that the companies have entered into an exclusive license agreement focused on the development of novel targeted therapies utilizing Ryvu's STING (STimulator of INterferon Genes) technology.
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2022
24 Jun 22
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
BMO Capital Initiates Coverage On Exelixis with Outperform Rating, Announces Price Target of $28
24 Jun 22
News, Price Target, Initiation, Analyst Ratings
BMO Capital analyst Etzer Darout initiates coverage on Exelixis (NASDAQ:EXEL) with a Outperform rating and announces Price Target of $28.
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
21 Jun 22
Biotech, News, Penny Stocks, Health Care, Small Cap, FDA, General
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session
Exelixis Announces Initiation Of STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 In Patients With Metastatic Colorectal Cancer
21 Jun 22
News, FDA
Exelixis, Inc. (NASDAQ:EXEL) today announced the initiation of STELLAR-303, a phase 3 pivotal trial evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic colorectal cancer
The Daily Biotech Pulse: Roche's Alzheimer's Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
16 Jun 22
Biotech, Large Cap, News, Penny Stocks, Health Care, Financing, Offerings, Small Cap, FDA, Insider Trades, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Exelixis-BioInvent Establish Immuno-Oncology Pact
16 Jun 22
Biotech, News, Penny Stocks, Health Care, Contracts, General
Exelixis and BioInvent Anounced Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
16 Jun 22
News
Exelixis, Inc. (Nasdaq: EXEL) and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the companies have entered into an option and license agreement focused on the identification and development of novel antibodies for use in IO therapeutics.
Exelixis Announces Results From Phase 2 Trial Of Cabozantinib In Combination With Pembrolizumab In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma At ASCO 2022
26 May 22
News, FDA
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022 – Results demonstrated an
12 Health Care Stocks Moving In Thursday's Intraday Session
19 May 22
Movers

Press releases

From Benzinga Pro
Exelixis Announces Second Quarter 2022 Financial Results and Provides Corporate Update
9 Aug 22
Press Releases
- Total Revenues of $419.4 million, Cabozantinib Franchise Revenues of $347.0 million - - GAAP Diluted EPS of $0.22, Non-GAAP Diluted EPS of $0.28 - - Conference Call and Webcast Today at 5:00 PM Eastern Time
Exelixis to Release Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
26 Jul 22
Press Releases
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its second quarter 2022 financial results will be released on Tuesday, August 9, 2022 after the
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
11 Jul 22
Press Releases
– Exelixis intends to discuss the results with the U.S. FDA to determine next steps toward a potential regulatory submission – – Trial to continue until the next analysis of the secondary endpoint of overall survival
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
7 Jul 22
Press Releases
– Provides additional opportunity for Exelixis to further expand its biotherapeutics development pipeline by combining its tumor-specific targeting approaches with Ryvu's STING agonist technology, which has
Exelixis to Webcast Fireside Chat as Part of the William Blair Biotech Focus Conference
5 Jul 22
Press Releases
-- Presentations to be webcast on www.exelixis.com -- Exelixis, Inc. (NASDAQ:EXEL) today announced that company management will participate in a pre-recorded fireside chat at the William Blair Biotech Focus Conference
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer
21 Jun 22
Press Releases
– STELLAR-303 is the first phase 3 pivotal trial evaluating XL092, a next-generation oral tyrosine kinase inhibitor – Exelixis, Inc. (NASDAQ:EXEL) today announced the initiation of STELLAR-303, a phase 3 pivotal trial
Exelixis and BioInvent Establish Exclusive Option and License Agreement to Develop Novel Antibody-Based Immuno-Oncology Therapies
16 Jun 22
Press Releases
- Exelixis positioned to expand its biotherapeutics development pipeline through selection of antibody candidates directed to targets identified using BioInvent's proprietary immuno-oncology (IO) screening platform and
Better Therapeutics Appoints Frank Karbe as Chief Executive Officer
7 Jun 22
Press Releases
Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in June
31 May 22
Press Releases
– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences in
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
26 May 22
Press Releases
– Cabozantinib in combination with atezolizumab demonstrated encouraging activity with a manageable safety profile in patients with locally advanced or metastatic urothelial carcinoma and patients with previously
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022
26 May 22
Press Releases
– Results demonstrated an objective response rate of 54% and an overall clinical benefit rate of 91% – Exelixis, Inc. (NASDAQ:EXEL) today announced results from a phase 2, investigator-sponsored trial of cabozantinib